KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Amortizatization of Intangibles (2018 - 2025)

Historic Amortizatization of Intangibles for Castle Biosciences (CSTL) over the last 6 years, with Q3 2025 value amounting to $905000.0.

  • Castle Biosciences' Amortizatization of Intangibles fell 4515.15% to $905000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 2365.91%. This contributed to the annual value of $6.7 million for FY2024, which is 2174.47% up from last year.
  • Latest data reveals that Castle Biosciences reported Amortizatization of Intangibles of $905000.0 as of Q3 2025, which was down 4515.15% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Amortizatization of Intangibles ranged from a high of $1.7 million in Q2 2024 and a low of $184000.0 during Q3 2022
  • In the last 4 years, Castle Biosciences' Amortizatization of Intangibles had a median value of $1.4 million in 2025 and averaged $1.3 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 75271.74% in 2023, then crashed by 4515.15% in 2025.
  • Castle Biosciences' Amortizatization of Intangibles (Quarter) stood at $1.2 million in 2022, then surged by 38.51% to $1.6 million in 2023, then fell by 1.65% to $1.6 million in 2024, then crashed by 43.89% to $905000.0 in 2025.
  • Its last three reported values are $905000.0 in Q3 2025, $1.2 million for Q2 2025, and $1.4 million during Q1 2025.